prikaz prve stranice dokumenta Bone morphogenetic protein 1.3 inhibition decreases scar formation and supports cardiomyocyte survival after myocardial infarction
  Download
PDF 3.11 MB
Scientific paper - Original scientific paper
Bone morphogenetic protein 1.3 inhibition decreases scar formation and supports cardiomyocyte survival after myocardial infarction
Nature Communications, 13 (2022), 1; 81. https://doi.org/10.1038/s41467-021-27622-9
Vukičević, Slobodan; Colliva, Andrea; Kufner, Vera; Martinelli, Valentina; Moimas, Silvia; Vodret, Simone; Rumenović, Viktorija; Milošević, Milan; Brkljačić, Boris; Delić-Brkljačić, Diana; Correa, Ricardo; Giacca, Mauro; Maglione, Manuel; Bordukalo-Nikšić, Tatjana; Dumić-Čule, Ivo; Zacchigna, Serena More authors...

Cite this document

Vukičević, S., Colliva, A., Kufner, V., Martinelli, V., Moimas, S., Vodret, S. ... Zacchigna, S. (2022). Bone morphogenetic protein 1.3 inhibition decreases scar formation and supports cardiomyocyte survival after myocardial infarction. Nature Communications, 13. (1). doi: 10.1038/s41467-021-27622-9

Vukičević, Slobodan, et al. "Bone morphogenetic protein 1.3 inhibition decreases scar formation and supports cardiomyocyte survival after myocardial infarction." Nature Communications, vol. 13, no. 1, 2022. https://doi.org/10.1038/s41467-021-27622-9

Vukičević, Slobodan, Andrea Colliva, Vera Kufner, Valentina Martinelli, Silvia Moimas, Simone Vodret, Viktorija Rumenović, et al. "Bone morphogenetic protein 1.3 inhibition decreases scar formation and supports cardiomyocyte survival after myocardial infarction." Nature Communications 13, no. 1 (2022). https://doi.org/10.1038/s41467-021-27622-9

Vukičević, S., et al. (2022) 'Bone morphogenetic protein 1.3 inhibition decreases scar formation and supports cardiomyocyte survival after myocardial infarction', Nature Communications, 13(1). doi: 10.1038/s41467-021-27622-9

Vukičević S, Colliva A, Kufner V, Martinelli V, Moimas S, Vodret S, and sur.. Bone morphogenetic protein 1.3 inhibition decreases scar formation and supports cardiomyocyte survival after myocardial infarction. Nature Communications [Internet]. 2022 January 10 [cited 2025 January 16];13(1). doi: 10.1038/s41467-021-27622-9

S. Vukičević, et al., "Bone morphogenetic protein 1.3 inhibition decreases scar formation and supports cardiomyocyte survival after myocardial infarction", Nature Communications, vol. 13, no. 1, January 2022. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:938875. [Accessed: 16 January 2025]

Please login to the repository to save this object to your list.
Metadata
Title (english)Bone morphogenetic protein 1.3 inhibition decreases scar formation and supports cardiomyocyte survival after myocardial infarction
AuthorSlobodan Vukičević
AuthorAndrea Colliva
AuthorVera Kufner
AuthorValentina Martinelli
AuthorSilvia Moimas
AuthorSimone Vodret
AuthorViktorija Rumenović
AuthorMilan Milošević
AuthorBoris Brkljačić
AuthorDiana Delić-Brkljačić
AuthorRicardo Correa
AuthorMauro Giacca
AuthorManuel Maglione
AuthorTatjana Bordukalo-Nikšić
AuthorIvo Dumić-Čule
AuthorSerena Zacchigna
Author's institutionUniversity of Zagreb
School of Medicine
(Department of Anatomy and Clinical Anatomy)
Author's institutionUniversity of Zagreb
School of Medicine
(Department of Internal Medicine)
Author's institutionUniversity of Zagreb
School of Medicine
(Department of Radiology)
Author's institutionUniversity of Zagreb
School of Medicine
(Department of Environmental and Occupational Health)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Internal Medicine
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Radiology
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Public Health and Health Care
Occupational and Sports Medicine
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Basic Medical Sciences
Anatomy
Abstract (english)
Abstract Despite the high prevalence of ischemic heart diseases worldwide, no antibody-based treatment currently exists. Starting from the evidence that a specific isoform of the Bone Morphogenetic Protein 1 (BMP1.3) is particularly elevated in both patients and animal models of myocardial infarction, here we assess whether its inhibition by a specific monoclonal antibody reduces cardiac fibrosis. We find that this treatment reduces collagen deposition and cross-linking, paralleled by enhanced cardiomyocyte survival, both in vivo and in primary cultures of cardiac cells. Mechanistically, we show that the anti-BMP1.3 monoclonal antibody inhibits Transforming Growth Factor β pathway, thus reducing myofibroblast activation and inducing cardioprotection through BMP5. Collectively, these data support the therapeutic use of anti-BMP1.3 antibodies to prevent cardiomyocyte apoptosis, reduce collagen deposition and preserve cardiac function after ischemia.
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titleNature Communications
Numberingvol. 13, no. 1, 81
e-ISSN2041-1723
DOIhttps://doi.org/10.1038/s41467-021-27622-9
URN:NBNurn:nbn:hr:105:938875
Publication2022-01-10
Document URLhttps://www.nature.com/articles/s41467-021-27622-9
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution 4.0 International (CC BY 4.0) icon
Created on2022-01-12 13:37:43